<DOC>
	<DOCNO>NCT02303054</DOCNO>
	<brief_summary>This prospective single center trial examine rate negative biopsy result quality life focal ablation radiofrequency energy . The primary evaluation involve assess rate negative biopsy result use MR-US fusion biopsy six month focal ablation prostate . Urinary sexual quality life assess validated measure . The hypothesis study focal ablative therapy result great likelihood negative biopsy followup biopsy observe men elect undergo therapy .</brief_summary>
	<brief_title>MRI-Targeted Focal Ablation Prostate Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subject Population : Men 4080 year age Diagnosis adenocarcinoma prostate , confirm TransRectal Ultrasound ( TRUS ) biopsy No prior treatment prostate cancer Prostate Cancer Clinical Stage T1c Prostatespecific antigen ( PSA ) &lt; 10 ng/ml ( PSA level prompt initial prostate biopsy ) Declined standard treatment option Preenrollment biopsy parameter : Minimum 12 biopsy core Gleason 6 ( 3+3 ) 7 ( 3+4 ) Final enrollment biopsy parameter fusion biopsy : 12 standard biopsy core plus targeted region base upon MRI Gleason 6 ( 3+3 ) 7 ( 3+4 ) No demonstrated cancer diameter &gt; 1.2 cm Histology adenocarcinoma Biopsy meet inclusion criterion History transurethral resection prostate ( TURP ) similar procedure transurethral microwave therapy ( TUMT ) , transurethral needle ablation ( TUNA ) History prior pelvic radiation Men receive hormonal manipulation ( antiandrogens ; luteinizing hormonereleasing hormone ( LHRH ) agonist ; 5alphareductase inhibitor ) within previous 12 month Contraindication MultiparametricMRI</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Focal Ablation</keyword>
	<keyword>MRI-US Fusion Biopsy</keyword>
	<keyword>Focal Therapy</keyword>
</DOC>